NBTX vs. GOSS, ATAI, ANL, ERAS, ENTA, XERS, NATR, PEPG, KMDA, and STOK
Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Gossamer Bio (GOSS), Atai Life Sciences (ATAI), Adlai Nortye (ANL), Erasca (ERAS), Enanta Pharmaceuticals (ENTA), Xeris Biopharma (XERS), Nature's Sunshine Products (NATR), PepGen (PEPG), Kamada (KMDA), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical preparations" industry.
Nanobiotix (NASDAQ:NBTX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
Nanobiotix has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
Nanobiotix has higher revenue and earnings than Gossamer Bio.
Nanobiotix's return on equity of 0.00% beat Gossamer Bio's return on equity.
Nanobiotix presently has a consensus target price of $11.00, suggesting a potential upside of 75.16%. Gossamer Bio has a consensus target price of $5.35, suggesting a potential upside of 287.68%. Given Gossamer Bio's higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Nanobiotix.
Gossamer Bio received 131 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 64.52% of users gave Gossamer Bio an outperform vote while only 60.00% of users gave Nanobiotix an outperform vote.
In the previous week, Gossamer Bio had 6 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Gossamer Bio and 1 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.93 beat Gossamer Bio's score of 0.59 indicating that Nanobiotix is being referred to more favorably in the media.
9.9% of Nanobiotix shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 9.5% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Gossamer Bio beats Nanobiotix on 8 of the 14 factors compared between the two stocks.
Get Nanobiotix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Nanobiotix Competitors List
Related Companies and Tools